Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) and reminds investors of the April 14, ...

We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to ...

On July 30, 2024, Merck released its second quarter 2024 financial report and disclosed a significant reduction in Gardasil vaccinations, resulting in an overabundance of inventory at Merck's Chinese ...

A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs ...

NEW YORK, NY / ACCESS Newswire / April 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

State of the City report underscores the city’s transformation into a launchpad for successful emerging businesses generating ...

Merck is in hot water after a class action lawsuit alleged securities fraud over its Gardasil revenue forecasts in China. The lawsuit claims Merck misled investors about its ability to achieve $11 ...

The Union Health Ministry plans to initiate capacity-building activities for frontline workers administering the HPV vaccine ...

Bernstein Liebhard LLP reminds Merck investors of an April 14, 2025 deadline to join a securities fraud class action lawsuit.

Gardasil, its vaccine for the human papillomavirus (HPV), may generate $11 billion in revenue by 2030, according to the company's estimates. Demand has, however, been a bit underwhelming of late ...

In its Q2 2024 earnings, MSD announced that sales for Gardasil were 17% lower (18% in exchange) compared to the previous year. At the time, the company attributed this to broader market headwinds ...

GSK’s restructuring of its distribution deal for its shingles vaccine Shingrix in December 2024, and MSD’s decision to pause sales of its blockbuster human papillomavirus (HPV) vaccine Gardasil until ...